Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 6, 2010, Pages 541-545

  Jeng, Wen Juei ^a   Sheen, I Shyan ^a   Liaw, Yun Fan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

HBeAg Seroconversion; HBV Load; Increased ALT; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS B; DECOMPENSATED LIVER CIRRHOSIS; DISEASE EXACERBATION; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PROTHROMBIN TIME; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; VIRUS LOAD;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BILIRUBIN; DNA, VIRAL; FEMALE; HEPATIC INSUFFICIENCY; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTHROMBIN; ROC CURVE; SERUM ALBUMIN; VIRAL LOAD; YOUNG ADULT;

EID: 77952742728     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.02.023     Document Type: Article

References (24)

1. Liaw Y.F., and Chu C.M. Hepatitis B infection. Lancet 14 (2009) 582-592
2. Liaw Y.F. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 18 (2003) 246-252
3. Liaw Y.F., Tai D.I., Chu C.M., et al. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology 7 (1987) 20-33
4. Lok A.S., and Lai C.L. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 10 (1990) 29-34
5. Nair S., and Perrillo R.P. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?. Hepatology 34 (2001) 1021-1026
6. Liaw Y.F., Leung N., Kao J.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2 (2008) 263-283
7. Sheen I.S., Liaw Y.F., Tai D.I., et al. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gasteroenterology 89 (1985) 732-735
8. Chu C.M., and Liaw Y.F. Increased incidence of fulminant hepatic failure in previous unrecognized HBsAg carriers with acute hepatitis independent of etiology. Infection 33 (2005) 136-139
9. Yuen M.F., Sablon E., Hui C.K., et al. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis 36 (2003) 979-984
10. Liaw Y.F. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 3 (2009) 425-433
11. Chien R.N., Lin C.H., and Liaw Y.F. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 38 (2003) 322-327
12. Lin D.Y., Sheen I.S., Chiu C.T., et al. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 21 (1993) 303-308
13. Tai D.I., Lin S.M., Sheen I.S., et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 49 (2009) 1859-1867
14. Chien R.N., Yeh C.T., Tsai S.L., et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38 (2003) 1267-1273
15. Ikegami T., Matsuki Y., Tanaka Y., et al. Impact of determination of hepatitis B virus subgenotype and pre-core/core-promoter mutation for the prediction of acute exacerbation of asymptomatic carriers. Hepatol Res 39 (2009) 341-345
16. Kusakaba A., Tanaka Y., Mochida S., et al. Case-control study for the identification of virological factors associated with fulminant hepatitis B. Hepatol Res 39 (2009) 648-656
17. Liaw Y.F., Chen J.J., and Chen T.J. Acute exacerbation in patients with liver cirrhosis: a clinicopathological study. Liver 10 (1990) 177-184
18. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
19. Chen Y.C., Chu C.M., Yeh C.T., et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 1 (2007) 267-273
20. Liaw Y.F. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 51 (2009) 403-410
21. Kim H.S., Kim H.J., Shin W.G., et al. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B. Gastroenterology 136 (2009) 505-512
22. Kao J.H. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 1 (2007) 415-430
23. Chu C.M., Yeh C.T., Lee C.S., et al. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-Anti-HBe seroconversion. J Clin Microbiol 40 (2002) 16-21
24. Tsai W.L., Lo G.H., Hsu P.I., et al. Role of genotype and precore/basal core promoter mutations of hepatitis B virus in patients with acute exacerbation. Scand J Gastroenterol 43 (2008) 196-201